Some of the key facts of the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report:

• The PH-ILD market size in the 7MM was approximately USD 1,400 million in 2023. PH-ILD Market is expected to increase by 2034 at a significant CAGR.
• According to DelveInsight's projections, the diagnosed prevalent cases of PH-ILD in the 7MM were estimated to be around 166,375 in the year 2021.
• Based on our analysis, the diagnosed prevalent population of PH-ILD in the United States was the highest among the 7MM, with an estimated 87,295 cases in 2021.
• In 2021, Germany had the largest diagnosed prevalent population of PH-ILD among the five major European countries, with 13,868 cases, followed by the United Kingdom, France, and Italy. Spain had the lowest number of PH-ILD cases in Europe, with 8,954 cases in the same year.
• In 2021, the highest number of type-specific cases of PH-ILD in the United States was attributed to IIPs, totaling 50,941 cases.
• During the forecast period, upcoming products like L606, TPIP, and others are expected to be launched.
• Key PH-ILD Companies: Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others
• Key PH-ILD Therapies: TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
• The PH-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline products will significantly revolutionize the Pulmonary Hypertension Associated with Interstitial Lung Disease market dynamics.
• In March 2025, Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has accepted its New Drug Application (NDA) resubmission for YUTREPIA (treprostinil) inhalation powder, intended to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

PH-ILD Overview

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) is a severe and progressive condition where high blood pressure develops in the lung's arterial system as a complication of underlying interstitial lung diseases (ILDs). This dual burden of vascular damage and lung fibrosis significantly worsens exercise capacity, oxygen requirements, and overall survival compared to ILD alone. Treatment strategies focus on managing the ILD itself, supportive measures like oxygen therapy and rehabilitation, and targeted vascular therapies. Early diagnosis is difficult but crucial for improving outcomes and slowing disease progression.

Get a Free sample for the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Forecast, Size & Share Analysis Report

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology

In 2024, in the US, the diagnosed prevalence of PH-ILD showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females, and this gender gap is expected to widen by 2034, suggesting potential differences in disease susceptibility or progression. In the same year, an estimated 69,000 people in the EU4 and the UK were diagnosed with PH-ILD, reflecting a substantial and growing disease burden across the region. In France, connective tissue disease–related PH-ILD recorded the highest diagnosed prevalence, at nearly 4,000 cases in 2024, whereas hypersensitivity pneumonitis was associated with the lowest burden, with just over 500 cases. Japan reported more than 28,000 diagnosed prevalent cases of PH-ILD in 2024, and the number is expected to rise further by 2034, indicating increasing public health concern. Idiopathic pulmonary fibrosis accounted for the largest share of PH-ILD cases in Japan at 21% in 2024, while hypersensitivity pneumonitis represented only 1%, highlighting notable variation in subtype distribution and the need for subtype-specific diagnostic and treatment approaches.

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Segmentation:

The Pulmonary Hypertension Associated with Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of PH-ILD
• Prevalent Cases of PH-ILD by severity
• Gender-specific Prevalence of PH-ILD
• Diagnosed Cases of Episodic and Chronic PH-ILD